Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Effect of Deramiocel on quality measures
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Effect of Deramiocel on quality measures

1 evidence topic · 1 source

Deramiocel-specific effects on quality measures

No evidence found.

Disease-state evidence: implementation of care considerations

“males with DMD and Becker muscular dystrophy” (opens the source at this quote in a new tab)
“Transition planning for education or health care was documented for 31% of eligible males.” (opens the source at this quote in a new tab)